Literature DB >> 10453076

Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.

F Bernassola1, C Scheuerpflug, I Herr, P H Krammer, K M Debatin, G Melino.   

Abstract

The CD95 (APO-1/Fas) system can mediate apoptosis in immune cells as well as in tumour cells, where it may contribute to tumour immune-escape. On the other hand, its induction by anticancer drugs may lead to tumour reduction. Interferongamma (IFNgamma) increases the sensitivity of tumour cell lines to anti-CD95 antibody-mediated apoptosis. We describe induction of apoptosis by IFNgamma through the expression of CD95 and its ligand (CD95L) in human neuroblastoma cell lines. Neuroblastoma cells showed low constitutive expression of CD95 and CD95L. Subsequent to IFNgamma-modulated increase in CD95 and CD95L mRNA as well as protein levels, apoptosis was observed. Our results demonstrated that cytokine-mediated apoptosis was mediated through the activation of the CD95/CD95L autocrine circuit since: (i) cell death occurred following CD95/CD95L expression and correlated with CD95 and CD95L expression levels, (ii) failed to occur in a clone which weakly upregulated CD95 and lacked CD95L induction after IFNgamma stimulation, (iii) was at least partially inhibited by using blocking F(ab')2 anti-CD95 antibody fragments and the recombinant Fas-Fc protein, that prevented the interaction between CD95 and CD95L. The intracellular molecular mechanisms elicited by IFNgamma are clearly highly complex, with several signalling pathways being activated, including the CD95 system. These findings suggest that IFNgamma may have a significant potential in the therapy of neuroblastoma in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10453076     DOI: 10.1038/sj.cdd.4400537

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  8 in total

1.  Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Authors:  Paola Bocca; Emma Di Carlo; Ignazio Caruana; Laura Emionite; Michele Cilli; Biagio De Angelis; Concetta Quintarelli; Annalisa Pezzolo; Lizzia Raffaghello; Fabio Morandi; Franco Locatelli; Vito Pistoia; Ignazia Prigione
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

2.  CD4+T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation.

Authors:  Jinpu Yu; Weihong Zhang; Huawei Jiang; Hui Li; Shui Cao; Xinbao Ren
Journal:  Cancer Biother Radiopharm       Date:  2008-06       Impact factor: 3.099

3.  Gene disruption of tissue transglutaminase.

Authors:  V De Laurenzi; G Melino
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

4.  TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.

Authors:  Koen Mo Galenkamp; Paulina Carriba; Jorge Urresti; Laura Planells-Ferrer; Elena Coccia; Joaquín Lopez-Soriano; Bruna Barneda-Zahonero; Rana S Moubarak; Miguel F Segura; Joan X Comella
Journal:  Mol Cancer       Date:  2015-03-19       Impact factor: 27.401

5.  Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Authors:  Randal K Gregg; Lisa Nichols; Yiming Chen; Bao Lu; Victor H Engelhard
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

6.  XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt.

Authors:  Atsushi Shiozaki; Grace Shen-Tu; Xiaohui Bai; Daisuke Iitaka; Valentina De Falco; Massimo Santoro; Shaf Keshavjee; Mingyao Liu
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

7.  Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Authors:  Anneleen Decock; Maté Ongenaert; Jasmien Hoebeeck; Katleen De Preter; Gert Van Peer; Wim Van Criekinge; Ruth Ladenstein; Johannes H Schulte; Rosa Noguera; Raymond L Stallings; An Van Damme; Geneviève Laureys; Joëlle Vermeulen; Tom Van Maerken; Frank Speleman; Jo Vandesompele
Journal:  Genome Biol       Date:  2012-10-03       Impact factor: 13.583

Review 8.  The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway.

Authors:  Laura Martin-Hijano; Bruno Sainz
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.